Biotech Tracker
Trial resultsSep 2026a window, not a day

ARO-MAPT Ph1 healthy-volunteer early data (tau knockdown) in September

Arrowhead reported results from its Phase 1 study of ARO-MAPT for Alzheimer's disease / tauopathies in Sep 2026. The linked source has what the numbers showed.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsClinical trial results · also called: readout / topline data
Company
Arrowhead Pharmaceuticals, Inc. ARWR
Drug
ARO-MAPT
For
Alzheimer's disease / tauopathies
Stage
Phase 1 · an early safety study in a small group of people
When
Sep 2026 · the company gave a window, not a day; the calendar never invents one
Source note
Fiscal Q3 2026 call (Aug 4, 2026) highlights via Yahoo Finance; first CNS (intrathecal) program data. Prior guidance was late Q3/early Q4 2026.
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
Arrowhead Pharmaceuticals, Inc.
ARWR
5 upcoming · 6 past catalysts
More from ARWR
MilestoneARWRArrowheadH2 2026

sNDA submission to FDA for plozasiran in severe hypertriglyceridemia, expected in the second half of 2026 (no exact date yet). A company milestone for Arrowhead (Plozasiran (Redemplo) for Severe hypertriglyceridemia): a step in the program rather than a decision or a data readout.

More details
Entry
sNDA submission to FDA for plozasiran in severe hypertriglyceridemia · Company milestone
Drug
Plozasiran (Redemplo)
For
Severe hypertriglyceridemia
Stage
Regulatory submission
When
H2 2026 · the company gave a window, not a day
Source note
Company PR (July 22, 2026): planned sNDA with U.S. FDA 'before the end of 2026,' leveraging SHASTA-3, SHASTA-4 and MUIR-3, with additional global filings to follow. A PDUFA date would follow acceptance (not yet assigned).
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsARWRArrowheadH2 2026

Arrowhead expects to report results from its Phase 3 study of Plozasiran (Redemplo) for Mixed hyperlipidemia (supportive for sHTG filing) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details
Entry
MUIR-3 Phase 3 topline: plozasiran in mixed hyperlipidemia · Clinical trial results (readout / topline data)
Drug
Plozasiran (Redemplo)
For
Mixed hyperlipidemia (supportive for sHTG filing)
Stage
Phase 3 · the last stage before a drug can be approved
When
H2 2026 · the company gave a window, not a day
Source note
Enrollment-completion PR guided primary completion of SHASTA-3/4 and MUIR-3 in mid-2026 'with topline data expected shortly thereafter.' SHASTA-3/4 topline is out (July 2026); MUIR-3 topline had not been published as of Aug 20, 2026. H2 2026 window inferred from that company guidance.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsARWRArrowheadQ4 2026

Arrowhead expects to report results from its Phase 1/2 study of ARO-ALK7 for Obesity in Q4 2026 (Oct–Dec) (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.

More details
Entry
ARO-ALK7 additional Ph1/2 obesity data in Q4 2026 · Clinical trial results (readout / topline data)
Drug
ARO-ALK7
For
Obesity
Stage
Phase 1/2 · an early study that checks safety and takes a first look at effect
When
Q4 2026 · the company gave a window, not a day
Source note
Fiscal Q3 2026 call (Aug 4, 2026). Management also flagged additional obesity-program updates in Q4; ARO-INHBE Phase 2b protocol submitted to regulators with start timing pending.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneARWRArrowheadH1 2027

Zodasiran Ph3 YOSEMITE HoFH study completion mid-2027, expected in the first half of 2027 (no exact date yet). A company milestone for Arrowhead (zodasiran for Homozygous familial hypercholesterolemia): a step in the program rather than a decision or a data readout.

More details
Entry
Zodasiran Ph3 YOSEMITE HoFH study completion mid-2027 · Company milestone
Drug
zodasiran
For
Homozygous familial hypercholesterolemia
Stage
Phase 3 · the last stage before a drug can be approved
When
H1 2027 · the company gave a window, not a day
Source note
Fiscal Q3 2026 release (Aug 4, 2026); enrollment completed mid-July 2026. 'mid-2027' mapped to 2027-H1; management said on the call that data follow in H2 2027 (outside this window).
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneARWRArrowheadQ2 2027

Potential accelerated Redemplo sHTG launch Q2 2027 (PRV priority review), expected in Q2 2027 (Apr–Jun) (no exact date yet). A company milestone for Arrowhead (plozasiran (Redemplo) for Severe hypertriglyceridemia): a step in the program rather than a decision or a data readout.

More details
Entry
Potential accelerated Redemplo sHTG launch Q2 2027 (PRV priority review) · Company milestone
Drug
plozasiran (Redemplo)
For
Severe hypertriglyceridemia
Stage
sNDA
When
Q2 2027 · the company gave a window, not a day
Source note
Fiscal Q3 2026 call (Aug 4, 2026): sNDA to be filed before year-end 2026 using an acquired priority review voucher (6-month review), which management said could enable an sHTG launch in Q2 2027. No PDUFA date yet.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page